BlackRock Updates ANI Pharma Stake as of Dec 31, 2023
Ticker: ANIP · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock just updated its ANI Pharma holdings, showing continued institutional interest.**
AI Summary
BlackRock Inc. has filed an Amendment No. 11 to its SC 13G filing for ANI Pharmaceuticals Inc., indicating its ownership stake as of December 31, 2023. This update, filed on January 23, 2024, shows BlackRock's continued significant, though passive, investment in ANI Pharmaceuticals. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal its confidence (or lack thereof) in the company's future prospects, potentially influencing other investors.
Why It Matters
This filing confirms BlackRock's ongoing, substantial investment in ANI Pharmaceuticals, providing transparency into a major institutional holder's position. It can reassure investors that a large, sophisticated firm sees value in the company.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate risk or significant change in company fundamentals.
Analyst Insight
A smart investor would note BlackRock's continued presence as a major shareholder, but recognize this is a passive investment update, not an active buy/sell signal. Further research into ANI Pharmaceuticals' fundamentals and recent performance would be prudent before making investment decisions.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- ANI Pharmaceuticals Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring this filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will likely maintain a significant, passive stake in ANI Pharmaceuticals for the foreseeable future. (BlackRock Inc.) — high confidence, target: 2024-12-31
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 11, as stated in the filing.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as indicated in the 'FILED BY' section of the document.
What is the subject company of this filing?
The subject company is ANI PHARMACEUTICALS INC, as stated under the 'SUBJECT COMPANY' and 'Name of Issuer' sections.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified in the document.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the checked box '[X] Rule 13d-1(b)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding ANI PHARMACEUTICALS INC (ANIP).